Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TeleflexTFX +0.01%76 EV-to-EBIT is 433.68 as of Jul. 29, 2026, which is 996% above its 10-year median of 39.57. GuruFocus rates TFX with a GF Score™ of 76/100 and a GF Value™ of $184.55 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Teleflex ranks worse than 99.15% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Teleflex's Enterprise Value for the quarter that ended in Mar. 2026 was $7,671 Mil.
Teleflex's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teleflex EV-to-EBIT Related Terms
Teleflex EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Teleflex's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Teleflex's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teleflex EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Teleflex's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Teleflex's EV-to-EBIT falls into.
Teleflex's current Enterprise Value is $8,318 Mil.
Teleflex's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teleflex (TFX) has a EV-to-EBIT of 433.68 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Teleflex and its competitors. This is 996% above median its historical median of 39.57. According to the industry distribution chart, Teleflex ranks #464 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 99.1%.
Is Teleflex's EV-to-EBIT too high?
Teleflex's current EV-to-EBIT of 433.68 is 996% above median its 10-year median of 39.57. The Medical Devices & Instruments industry median EV-to-EBIT is 18.70. Teleflex's value of 433.68 is 2219.8% above this industry median. Based on the distribution chart, Teleflex ranks #464 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Teleflex has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Teleflex's EV-to-EBIT compare to STVN and MMED?
According to the Medical Devices & Instruments industry distribution chart, Teleflex ranks #464 out of 468 companies for EV-to-EBIT. This places Teleflex in the lower half of its industry. The industry median EV-to-EBIT is 18.70. Teleflex's value of 433.68 is 2219.8% above this benchmark. While the company's 10-year median is 39.57 vs. the industry median of 18.70, Teleflex has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.70, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teleflex's current EV-to-EBIT of 433.68 is 2219.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Teleflex and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teleflex's current EV-to-EBIT is 433.68, which is 996% above median its own 10-year median of 39.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teleflex stock overvalued right now?
Based on GuruFocus' analysis, Teleflex (TFX) is currently considered Modestly Undervalued. The stock's GF Value™ is $184.55, compared to a current price of $134.22 — trading 27.3% below its estimated fair value. The current EV-to-EBIT is 433.68, which is 996% above median its 10-year median of 39.57 and 2219.8% above the Medical Devices & Instruments industry median of 18.70. Teleflex's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Teleflex (TFX), the current EV-to-EBIT is 433.68 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teleflex (TFX) Overvalued in 2026?
Based on GuruFocus' analysis, Teleflex stock appears to be undervalued.
The current stock price of $134.22 is trading 27.3% below its estimated GF Value™ of $184.55.
GuruFocus considers Teleflex to be Modestly Undervalued.
Key valuation signals for TFX:
EV-to-EBIT: 433.68 (996% above median its 10-year median of 39.57)
GF Value™: $184.55 vs. price of $134.22 (27.3% below fair value)
Industry Position: 2219.8% above the Medical Devices & Instruments median (#464 of 468)
No single metric tells the full story. See the TFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
76GF Score
Get the complete analysis for TFX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TFX has been successfully added to your 
